China Earnings Overview: Pfizer, Roche Lead Growth With Very Different Strategies
This article was originally published in PharmAsia News
PharmAsia News takes a closer look at how Big Pharma performed in China during Q2. Roche, Pfizer and Novartis were the fastest-growing companies among Big Pharma in China.
You may also be interested in...
Pfizer China Country Manager Wu Xiaobing And General Manager For Commercial And Diversified Business Kevin Xiao On Expansion To Rural Markets In China: An Interview With PharmAsia News
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.